Back to Search
ROBERT FIGLIN, MD
MD
Hematology & Oncology Physician
NPI: 1780609966IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
G35300(CA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
MEDICAL COLLEGE OF PENNSYLVANIA
Class of 1976
Research & Publications (20)
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
PMID 19526589·Cancer·2009
3-trial
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
PMID 18607393·Nat Clin Pract Oncol·2008
6-review
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.
PMID 18602688·Lancet·2008
3-trial
Newly approved therapies for RCC and their effect on the standard of care.
PMID 17339824·Clin Adv Hematol Oncol·2007
8-other
Renal cell carcinoma: the translation of biology to clinical application.
PMID 17045080·Semin Oncol·2006
8-other
Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
PMID 15179554·Urologe A·2004
8-other
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
PMID 19402064·Cancer·2009
8-other
Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
PMID 19479976·Cancer·2009
6-review
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PMID 19487381·J Clin Oncol·2009
3-trial
NCCN clinical practice guidelines in oncology: testicular cancer.
PMID 19555582·J Natl Compr Canc Netw·2009
6-review
Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach.
PMID 19370179·Curr Oncol·2009
8-other
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
PMID 19244102·Cancer Res·2009
7-preclinical
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.
PMID 19229667·Med Oncol·2009
3-trial
NCCN clinical practice guidelines in oncology: kidney cancer.
PMID 19555584·J Natl Compr Canc Netw·2009
6-review
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
PMID 19213665·Clin Genitourin Cancer·2009
3-trial
CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.
PMID 19563666·BMC Cancer·2009
8-other
The role of targeting mammalian target of rapamycin in lung cancer.
PMID 19073516·Clin Lung Cancer·2008
6-review
NCCN Task Force Report: mTOR inhibition in solid tumors.
PMID 18926092·J Natl Compr Canc Netw·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1500 E DUARTE RD
DUARTE, CA 91010 - Phone
- (626) 359-8111
Quick Facts
- NPI
- 1780609966
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 50
- Publications
- 20
Are you this provider?
Claim Your Profile